Berberine
Evidence Fact Sheet
Berberis alkaloid
Berberine is a plant alkaloid (from Berberis species) studied as a metabolic-support supplement. Meta-analyses in type 2 diabetes show fasting-glucose, HbA1c and lipid reductions; honest negatives include no change in body weight and probiotic-alone failing. Not GRAS; regulated as a drug in CN/BR.
Also known as: Berberine HCl · Berberine sulfate · Dihydroberberine (DHB)
Overview
Berberine is an isoquinoline alkaloid extracted from Berberis and related plants (goldenseal, Coptis, Oregon grape). Its most-studied mechanism is activation of AMP-activated protein kinase (AMPK), with downstream suppression of hepatic gluconeogenesis, modulation of the gut microbiome, and PCSK9-mediated effects on LDL clearance — placing most research in glycemic regulation, lipid management, and metabolic-syndrome support. Typical research dosing is 500 mg three times daily (1500 mg/day) with meals; the better-absorbed dihydroberberine form is studied at 100-200 mg/day because oral berberine bioavailability is very low. Gastrointestinal upset (constipation/diarrhea) is common and berberine inhibits CYP3A4/CYP2D6, creating drug-interaction potential. Regulatory status varies sharply: a DSHEA dietary supplement (not GRAS) in the US, not authorized for supplement claims in the EU, and treated as an OTC drug rather than a supplement in China and not on the authorized-constituent list in Brazil.
Mechanism of Action
AMPK activation · Hepatic gluconeogenesis suppression · Gut microbiome modulation · PCSK9 mRNA suppression (lipid effect)
Body systems: METABOLISM · Endocrine & Metabolic · Cardiovascular · Digestive & Gut
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Berberine is not characterized as a treatment for any disease.
Glycemic Regulation (Type 2 Diabetes)
Meta-analysis supported- MD -0.86 mmol/Lfasting glucose
- MD -0.73HbA1c (%)
- 46 trialspooled RCTs
In a meta-analysis of 46 trials in type 2 diabetic patients, berberine was associated with significant reductions in fasting plasma glucose, HbA1c, 2-hour postprandial glucose, fasting insulin and HOMA-IR versus controls. This is berberine's strongest and most-replicated research signal.
Reported effect: FPG MD = -0.86 (95% CI -1.10 to -0.62); HbA1c MD = -0.73 (95% CI -0.97 to -0.51); HOMA-IR MD = -0.71 (95% CI -1.03 to -0.39); 46 trials assessed
“Forty-six trials were assessed. ... significant reductions in HbA1c (MD = -0.73; 95% CI (-0.97, -0.51)) ... FPG (MD = -0.86, 95% CI (-1.10, -0.62)) ... lowering FINS (MD = -2.05, 95% CI (-2.62, -1.48)) ... HOMA-IR (MD = -0.71, 95% CI (-1.03, -0.39))”
Source: PMID 34956436 · Guo 2021 · Oxid Med Cell Longev
Glycemic & Insulin Traits (Sex-Specific)
Meta-analysis supported- -0.52 mmol/Lfasting glucose · 18 studies
- -0.85HOMA-IR · 12 studies
A 2023 meta-analysis (20 studies, n=1,761) confirmed berberine's reductions in fasting glucose, HbA1c, fasting insulin and HOMA-IR, and reported a potentially larger glycemic effect in women than in men — an emerging sex-difference signal that warrants confirmation.
Reported effect: Fasting glucose -0.52 mmol/L (95% CI -0.72 to -0.33); HbA1c -4.48 mmol/mol (-6.53 to -2.44); fasting insulin -2.36 mU/L (-3.64 to -1.08); HOMA-IR -0.85 (-1.16 to -0.53)
“Fasting glucose -0.52 mmol/L (-0.72 to -0.33) [18 studies, N=1,522]; HbA1c -4.48 mmol/mol (-6.53 to -2.44); fasting insulin -2.36 mU/L (-3.64 to -1.08); HOMA-IR -0.85 (-1.16 to -0.53). Effects on fasting glucose and HOMA-IR showed potential differences by sex, with larger reductions in women than in men.”
Source: PMID 37598753 · Zhao 2023 · J Nutr
Blood Lipids / Cholesterol
Meta-analysis supported- MD -14.98 mg/dLLDL-C
- MD -17.42 mg/dLtotal cholesterol
- 41 RCTs · n=4,838pooled
In a meta-analysis of 41 RCTs (4,838 patients), berberine or berberine-combination products significantly lowered total cholesterol, LDL-C and triglycerides while modestly raising HDL-C. Effects are clinically modest and partly driven by combination formulations.
Reported effect: TC MD -17.42 mg/dL (95% CI -22.91 to -11.93); LDL MD -14.98 mg/dL (-20.67 to -9.28); TG MD -18.67 mg/dL (-25.82 to -11.51); HDL MD +1.97 mg/dL (1.16 to 2.78); 41 RCTs, 4,838 patients
“Berberine containing products significantly reduced TC (MD -17.42 mg/dL [95%CI: -22.91 to -11.93]), LDL (MD -14.98 mg/dL [95%CI: -20.67 to -9.28]), TG (MD -18.67 mg/dL [95%CI: -25.82 to -11.51]) ... raising HDL (MD 1.97 mg/dL [95%CI: 1.16 to 2.78])”
Source: PMID 37183391 · Hernandez 2024 · J Diet Suppl
Body Weight / Obesity
Null / no benefit Meta-analysis supported- WMD -0.11 kgbody weight · p=0.79 (NS)
- WMD -0.29 kg/m²BMI · p=0.006
- WMD -2.75 cmwaist · p=0.01
Honest negative: a dose-response meta-analysis (10 studies) found NO significant effect of berberine on body weight (p=0.79). Only small reductions in BMI and waist circumference reached significance, so berberine is not a weight-loss agent despite popular framing.
Reported effect: Body weight WMD -0.11 kg (95% CI -0.99 to 0.76, p=0.79, non-significant); BMI WMD -0.29 kg/m² (-0.51 to -0.08, p=0.006); waist WMD -2.75 cm (-4.88 to -0.62, p=0.01)
“berberine supplementation yielded no significant decline in body weight (BW) (WMD: -0.11 kg, 95% CI: -0.99 to 0.76, p = 0.79) ... significant influence of berberine administration on body mass index (BMI) (WMD: -0.29 kg/m2, 95% CI: -0.51 to -0.08, p = 0.006) ... waist circumference (WC) (WMD: -2.75 cm, 95% CI: -4.88 to -0.62, p = 0.01)”
Source: PMID 32379652 · Xiong 2020 · Complement Ther Clin Pract
Inflammation (C-Reactive Protein)
Meta-analysis supported- MD -0.64 mg/LCRP · p<0.001
- 5 RCTspooled · I²=0%
A meta-analysis of 5 RCTs found berberine supplementation significantly lowered serum C-reactive protein, a marker of chronic inflammation, with no statistical heterogeneity (I²=0%). The pooled sample size was not reported in the abstract.
Reported effect: CRP MD -0.64 mg/L (95% CI -0.67 to -0.61, P<0.001); 5 RCTs; I²=0.0%
“Pooled analysis showed that serum levels of CRP were decreased after BER supplementation (MD:-0.64 mg/L, 95% CI(-0.67 to -0.61) P < 0.001)”
Source: PMID 31519292 · Beba 2019 · Complement Ther Med
Polycystic Ovary Syndrome (Fertility)
Meta-analysis supported- RR 1.96clinical pregnancy
- RR 1.41ovulation rate
- 10 RCTs · n=713pooled
In a meta-analysis of 10 RCTs (713 women with PCOS), berberine as adjuvant therapy was associated with higher clinical pregnancy and ovulation rates, increased endometrial thickness, and reduced LH and testosterone. Framed by authors as an adjuvant, not a standalone fertility treatment.
Reported effect: Clinical pregnancy RR 1.96 (95% CI 1.59-2.41); ovulation RR 1.41 (1.26-1.60); endometrial thickness WMD 1.62 mm (1.39-1.85); total testosterone SMD -0.70 (-1.02 to -0.39); 10 RCTs, n=713
“Clinical pregnancy rate: RR 1.96; 95 % CI 1.59-2.41 ... Ovulation rate: RR 1.41; 95 % CI 1.26-1.60 ... total testosterone standard mean difference -0.70; 95 % CI -1.02 to -0.39. Berberine may serve as an adjuvant therapy to enhance ovulation and increase clinical pregnancy rates in women with PCOS.”
Source: PMID 39236662 · Ha 2024 · Explore (NY)
Gut Microbiome & Glycemic Control (Large RCT)
Null / no benefit RCT supported- -0.99% HbA1cberberine vs -0.59% placebo
- -0.53% HbA1cprobiotic alone = placebo (NS)
The PREMOTE RCT (n=409, 4 arms) found berberine — alone or with probiotics — lowered HbA1c significantly more than placebo in newly diagnosed type 2 diabetes. Honest negative within the same trial: probiotics alone gave no advantage over placebo, isolating berberine as the active component.
Reported effect: HbA1c change: probiotics+BBR -1.04% (95% CI -1.19 to -0.89); BBR alone -0.99% (-1.16 to -0.83); placebo -0.59% (-0.75 to -0.44); probiotics alone -0.53% (-0.68 to -0.37); P<0.001
“The changes in glycated haemoglobin, as the primary outcome, in the probiotics+BBR and BBR-alone group were significantly greater than that in the placebo and probiotics-alone groups. ... BBR alone -0.99% [95% CI, -1.16 to -0.83]; placebo -0.59% [-0.75 to -0.44]; probiotics alone -0.53% [-0.68 to -0.37]; P < 0.001”
Source: PMID 33024120 · Zhang 2020 · Nat Commun
Bioavailability & Dihydroberberine Form
Null / no benefit RCT supported- p=0.97acute glucose (no change)
A pharmacokinetic crossover RCT (5 males) showed dihydroberberine 100 mg produced far higher plasma berberine exposure than berberine 500 mg (AUC 284 vs 42 ng/mL×min). Honest negative: neither form changed acute glucose or insulin in this fasted protocol, underscoring that low oral bioavailability is a real limitation.
Reported effect: Peak plasma berberine D100 3.76 vs B500 0.4 ng/mL (p=0.005); AUC D100 284.4 vs B500 42.3 ng/mL×120 min (p=0.04); no significant change in glucose (p=0.97) or insulin (p=0.24); n=5
“D100 (3.76 ± 1.4 ng/mL) was different than ... B500 (0.4 ± 0.17 ng/mL, p = 0.005) ... berberine AUC ... between D100 (284.4 ± 115.9 ng/mL × 120 min) ... and B500 (42.3 ± 17.6 ng/mL × 120 min, p = 0.04). No significant differences in the levels of glucose (p = 0.97) and insulin (p = 0.24) were observed”
Source: PMID 35010998 · Moon 2021 · Nutrients
Dosage (research context · not a recommendation)
500 mg t.i.d. (1500 mg/day total) standard; dihydroberberine 100-200 mg/day better absorbed; take with meals
Regulatory Status · 4 Markets
- US · FDA
- DSHEA dietary supplement; not GRAS; FDA warning letters on diabetes/cholesterol disease claims
- EU · EFSA
- Not authorized as food supplement claim; Novel Food considerations
- CN · China
- China SAMR: berberine HCl is an OTC drug for intestinal infection, not a supplement. No dietary-supplement/common-food pathway (absent from GB 2760, GB 14880, health-food raw-material catalogue); only cross-border e-commerce import.
- BR · ANVISA
- Berberine is NOT on the ANVISA IN 28/2018 authorized-constituent positive list (a nao-autorizado constituent for food supplements); the RDC 243/2018 framework exists but berberine itself has no compliant dietary-supplement pathway.
Safety
GI upset (constipation/diarrhea) common; CYP3A4/CYP2D6 inhibition (drug interactions · metformin, statins, immunosuppressants); contraindicated in pregnancy (uterotonic theoretical); not equivalent to metformin (despite popular framing)
Related
Goals: weight-management · heart-health · glp-1-companion
Lifestyles: glp-1-companion · weight-management
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 34956436 · Guo 2021 · Oxid Med Cell Longev — Glycemic Regulation (Type 2 Diabetes)
- PMID 37598753 · Zhao 2023 · J Nutr — Glycemic & Insulin Traits (Sex-Specific)
- PMID 37183391 · Hernandez 2024 · J Diet Suppl — Blood Lipids / Cholesterol
- PMID 32379652 · Xiong 2020 · Complement Ther Clin Pract — Body Weight / Obesity
- PMID 31519292 · Beba 2019 · Complement Ther Med — Inflammation (C-Reactive Protein)
- PMID 39236662 · Ha 2024 · Explore (NY) — Polycystic Ovary Syndrome (Fertility)
- PMID 33024120 · Zhang 2020 · Nat Commun — Gut Microbiome & Glycemic Control (Large RCT)
- PMID 35010998 · Moon 2021 · Nutrients — Bioavailability & Dihydroberberine Form
Frequently Asked Questions
1. What is berberine and where does it come from?
Berberine is a yellow isoquinoline alkaloid found in plants such as Berberis (barberry), Coptis (goldthread), Oregon grape and goldenseal. In research it is studied mainly for metabolic endpoints — blood glucose, blood lipids and inflammatory markers — with its best-characterized mechanism being activation of AMP-activated protein kinase (AMPK), plus effects on the gut microbiome and on LDL clearance.
2. What does the strongest evidence actually show?
The most consistent, well-replicated signal is glycemic: a meta-analysis of 46 trials in type 2 diabetes found significant reductions in fasting glucose (MD -0.86 mmol/L), HbA1c (MD -0.73) and HOMA-IR (Guo 2021, PMID 34956436), and a 2023 meta-analysis of 20 studies (n=1,761) confirmed this. Lipid meta-analyses (41 RCTs, n=4,838; Hernandez 2024) show modest LDL and triglyceride reductions. These are research findings in studied populations, not a treatment claim.
3. Does berberine cause weight loss?
Not according to the strongest data. A dose-response meta-analysis (Xiong 2020, PMID 32379652) found NO significant effect on body weight (WMD -0.11 kg, p=0.79). Only small reductions in BMI (-0.29 kg/m²) and waist circumference (-2.75 cm) were significant. Despite its popularity as a 'natural Ozempic,' berberine is not a weight-loss agent in the trial evidence.
4. Why are absorption and the 'dihydroberberine' form a big deal?
Oral berberine has very low bioavailability. A pharmacokinetic RCT (Moon 2021, PMID 35010998) showed dihydroberberine 100 mg produced roughly 5x the plasma berberine exposure of berberine 500 mg. That is why the card lists dihydroberberine at 100-200 mg/day versus 1500 mg/day for standard berberine — though that same study found neither form changed acute glucose in a short fasted test.
5. What are the main safety and regulatory considerations?
Gastrointestinal upset (constipation/diarrhea) is the most common adverse effect. Berberine inhibits the CYP3A4 and CYP2D6 drug-metabolizing enzymes, creating interaction potential with medications such as statins, metformin and immunosuppressants, and it is theoretically contraindicated in pregnancy (uterotonic). Regulatory status differs by market: a DSHEA dietary supplement (not GRAS) in the US, not authorized for supplement claims in the EU, and treated as an OTC drug — not a supplement — in China, with no compliant supplement pathway in Brazil.
Last evidence review: 2026-05-29